Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
carvykti
Synonyms :
ciltacabtagene autoleucel
Class :
Antineoplastic
Brand Name :
carvykti
Synonyms :
ciltacabtagene autoleucel
Class :
Antineoplastic
Dosage Forms & StrengthsÂ
InjectionÂ
1X108 CAR-viable positive T cells per single infusionÂ
Administer within 2.5 hoursÂ
Injection
Treatment includes lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by ciltacabtagene autoleucel IV infusion
Lymphodepleting chemotherapy
Fludarabine: 30mg/m2 Intravenous every day for three days
Cyclophosphamide: 300mg/m2 Intravenous every day for 3 days
Ciltacabtagene autoleucel
After 2-4 days of Lymphodepleting chemotherapy, administer
0.5-1X106 CAR-positive viable T cells/kg intravenous
Do not exceed 1X108 CAR- T cells per single infusion
Dosage Forms & StrengthsÂ
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may increase the toxic effect
may increase the toxic effect
may increase the toxic effect
may increase the toxic effect
may increase the toxic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may increase the toxic effect of immunosuppressants
may decrease the therapeutic effect
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may increase the immunosuppressive effects
may decrease the therapeutic effect
may increase the toxic effect of immunosuppressants
may increase the immunosuppressive effects
may increase the toxic effect of immunosuppressants
It may enhance the immunosuppressive effects when combined with risankizumab
clofarabine and ciltacabtagene autoleucel increase the effect of each other by immunosuppression
By immunosuppressive effects, the effects of the other drug increases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
when melphalan is combined with ciltacabtagene autoleucel, the risk or severity of adverse effects can be increased
when both the drugs combine the effect of both drugs increases by immunosuppressive effects
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection  
increases the risk of serious infection due to immunosuppressionÂ
interaction raises immunosuppressive effects and risk of infection
either of the drug in combination increases the effect of the other due to immunosuppression/risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
either of the drug in combination increases the effect of the other due to immunosuppression/risk of infection
when both drugs are combined, there may be an increased risk of adverse effects  
when both drugs are combined, there may be an increased risk of infection Â
when both drugs are combined, there may be an increased risk of adverse effects 
may increase the immunosuppressive effects of each other
may enhance the immunosuppressive effects of each other
may diminish the activity of each other
may enhance the immunosuppressive effects of each other
may decrease the therapeutic effect
may increase the immunosuppressive effects
Frequency defined:Â Â
>10%Â
Any gradeÂ
CRSÂ
HypotensionÂ
FatigueÂ
CoughÂ
DiarrheaÂ
EncephalopathyÂ
Upper respiratory tract infectionÂ
HeadacheÂ
Viral infectionsÂ
DyspneaÂ
Nasal congestionÂ
InsomniaÂ
HypoxiaÂ
PyrexiaÂ
Musculoskeletal painÂ
ChillsÂ
NauseaÂ
Decreased appetiteÂ
Grade≥3Â
NeutropeniaÂ
AnemiaÂ
Increased ASTÂ
PneumoniaÂ
LymphopeniaÂ
Decreased white blood cellsÂ
Thrombocytopenia Â
1-10%Â
Any gradeÂ
Bacterial infectionsÂ
Febrile neutropeniaÂ
SepsisÂ
Grade≥3Â
HypotensionÂ
FatigueÂ
CoughÂ
DiarrheaÂ
EncephalopathyÂ
Upper respiratory tract infectionÂ
HeadacheÂ
Viral infectionsÂ
DyspneaÂ
ConstipationÂ
HypertensionÂ
Nasal congestionÂ
Other adverse reactionsÂ
ThrombosisÂ
Renal failureÂ
SeizureÂ
RashÂ
DeliriumÂ
AtaxiaÂ
BradykinesiaÂ
TremorÂ
Peripheral neuropathyÂ
DysphagiaÂ
Chest painÂ
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: ciltacabtagene autoleucelÂ
Pronounced: [ SIL-ta-KAB-ta-jeen-AW-toe-LOO-sel ]Â
Why do we use ciltacabtagene autoleucel?Â
It is used to treat multiple myeloma in adultsÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
